Israel Peptic Ulcer Treatment Market is expected to be Dominated by Antibiotics Type through 2028
Increasing incidence of peptic ulcers
across the country is expected to drive the growth of the Israel peptic ulcer
treatment market during the forecast
period, 2018-2028.
According
to TechSci Research report, “Israel Peptic Ulcer Treatment Market - By Region,
Forecast and Opportunities, 2018-2028”, the Israel peptic
ulcer treatment market is expected to grow with an impressive CAGR during the
forecast period 2018-2028. The rising prevalence of peptic ulcer diseases and
the growing awareness among the key market players, including manufacturers who
are involved in new drug production with high efficacy, acquisitions,
expansions, strategic collaborations, and recent developments show the growth
of the Israel peptic ulcer treatment market.
However, one of the main
contributing factors to the increasing awareness is rising for minimally
invasive procedures for the treatment of peptic ulcers. In addition, unhealthy
lifestyles, such as a diet high in salt and saturated fat, sedentary behavior,
and smoking, are major risk factors for peptic ulcers that has enhanced the growth of the Israel peptic
ulcer treatment market during the forecast period.
Additionally, another important factor contributing
to the growth of the Israel peptic ulcer treatment market is the increasing
prevalence of Helicobacter pylori (H. pylori) infection. H. pylori is a gram-negative microaerophilic bacterium that colonizes
the gastric mucosa. H. pylori infection is generally acquired during childhood
and persists life-long in the absence of treatment with antibiotics. According
to the research article, approximately 89% of all gastric cancers are
attributed to H. pylori infection and the eradication of this
infection has been known to reduce peptic ulcers and gastric cancer incidence
as well. Therefore, the development of peptic ulcer treatments leads to the
growth of the Israel peptic ulcer treatment market.
Browse
over 30 market data Figures spread through 70 Pages and an in-depth TOC on
"Israel Peptic Ulcer Treatment Market”
The Israel
peptic ulcer treatment market can be segmented by product
type, disease indication, end user, and region. By product type, the market
can be segmented into proton pump inhibitors, H2 antagonists, antibiotics, and others.
Based on disease indication, the market can be segmented into gastritis,
gastric ulcer, duodenal ulcer, and gastroesophageal reflux disease (GERD). In
terms of end users, the market can be segmented into hospital pharmacies,
retail pharmacies, and online pharmacies.
Based
on product type, the market can be segmented into proton pump inhibitors, H2 antagonists,
antibiotics, and others. The antibiotics segment occupied the largest share of
the Israel peptic ulcer treatment market share in 2018, as it acts as first
line of treatment and recover the ulcers smoothly. Additionally, proton pump
inhibitors stand for second-line treatment, which is further expected to grow
at a significant CAGR during the forecast period.
Based
on disease indication, the market can be segmented into gastritis, gastric
ulcer, duodenal ulcer, and gastroesophageal reflux disease (GERD). The duodenal
ulcer segment occupied the largest peptic ulcer treatment market share in 2018,
due to rising prevalence of duodenal ulcers, increasing awareness, and
therapeutic launches for its treatments are the major factors predicted for
this segment’s growth. However, the duodenal ulcer segment is expected to
continue its dominance during the forecast period.
Based
on the end user, the market can be segmented into hospital pharmacies, retail
pharmacies, and online pharmacies. The hospitals pharmacy segment is projected
to hold a significant market share during the forecast period.
Major
companies operating in the Israel peptic ulcer treatment market include:
- Pfizer Pharmaceuticals Israel Ltd
- MERCK SERONO LTD.
- AstraZeneca Israel Inc
- Novartis Pharma Israel Ltd
- Sanofi-Aventis Israel Ltd
- Boehringer Ingelheim Israel Ltd.
- Bristol-Myers Squibb Israel Ltd.
- Takeda Israel Inc.
- Teva Israel Ltd.
- Servier Israel Inc.
Download Sample Report
Customers can also request for 10% free
customization in this report.
“The
Israel peptic ulcer treatment market is expected to witness significant growth
during the forecast period due to increasing number of masses toward minimally
invasive treatments. An increase in awareness of the health risks associated
with stomach ulcers supports the demand for peptic ulcer treatment in Israel.
Additionally, an increase in the emergence of players for developing new
techniques to treat ulcers is expected to create lucrative opportunities for
the market growth in the next few years” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based global management consulting
firm.
“Israel
Peptic Ulcer Treatment Market, By Product Type (Proton Pump Inhibitors, H2
Antagonists, Antibiotics, Others), By Disease Indication (Gastitis, Gastric Ulcer,
Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD), By End User (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition,
Forecast and Opportunities, 2028”, has evaluated the future growth
potential of the Israel Peptic Ulcer Treatment Market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in the Israel peptic ulcer treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com